HealthCor Management L.P. Has $20.41 Million Stake in The Medicines Company (MDCO)

HealthCor Management L.P. lowered its holdings in shares of The Medicines Company (NASDAQ:MDCO) by 32.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 682,200 shares of the company’s stock after selling 321,748 shares during the period. HealthCor Management L.P.’s holdings in The Medicines were worth $20,405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bailard Inc. acquired a new stake in The Medicines during the second quarter worth approximately $1,193,000. Schwab Charles Investment Management Inc. grew its stake in The Medicines by 2.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 343,474 shares of the company’s stock worth $12,606,000 after purchasing an additional 6,830 shares during the period. SG Americas Securities LLC grew its stake in The Medicines by 144.4% during the second quarter. SG Americas Securities LLC now owns 12,462 shares of the company’s stock worth $457,000 after purchasing an additional 7,362 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in The Medicines during the third quarter worth approximately $818,000. Finally, 683 Capital Management LLC grew its stake in The Medicines by 8.5% during the second quarter. 683 Capital Management LLC now owns 127,252 shares of the company’s stock worth $4,670,000 after purchasing an additional 10,000 shares during the period.

Shares of The Medicines stock opened at $19.06 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23. The Medicines Company has a 52 week low of $18.64 and a 52 week high of $41.57.



The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.13). The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The firm had revenue of ($3.30) million during the quarter, compared to analyst estimates of $1.88 million. During the same period last year, the business posted ($1.19) EPS. The company’s revenue was down 141.8% on a year-over-year basis. Sell-side analysts predict that The Medicines Company will post -2.91 EPS for the current fiscal year.

In other news, EVP Christopher T. Cox acquired 50,300 shares of The Medicines stock in a transaction on Friday, November 16th. The stock was purchased at an average price of $19.73 per share, with a total value of $992,419.00. Following the completion of the purchase, the executive vice president now owns 60,308 shares of the company’s stock, valued at approximately $1,189,876.84. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.29% of the company’s stock.

MDCO has been the subject of several recent analyst reports. Zacks Investment Research cut The Medicines from a “hold” rating to a “sell” rating in a research note on Wednesday, November 21st. BidaskClub cut The Medicines from a “sell” rating to a “strong sell” rating in a research note on Friday, September 28th. ValuEngine cut The Medicines from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. Oppenheimer set a $50.00 target price on The Medicines and gave the stock a “buy” rating in a research note on Friday, November 9th. Finally, Cowen set a $46.00 target price on The Medicines and gave the stock a “buy” rating in a research note on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $49.67.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/12/16/healthcor-management-l-p-has-20-41-million-stake-in-the-medicines-company-mdco.html.

The Medicines Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply